P PRIMESTOCKFINDER.COM

IMM Shares Immutep Limited

ASX · ASX
$0.02 +0.00% Prices as of close 2026-10-26

Last in our picks 2026-10-19 — not in the current list; analysis below is from that screen

Late-stage immuno-oncology assets offer meaningful upside if trial execution and partnership momentum continue.

Signal breakdown

  • ▸Late-stage immuno-oncology clinical progress remains the key catalyst.
  • ▾Below 50-day MA (-44.9%)
  • ▾Near 52-week low (0.2% of range)

Is IMM a buy right now?

Trend: IMM is trading below the 50-day average (-42.50%), RSI 36 — neutral momentum, with a 3-month return of -50.00%.

Valuation & quality: Immutep Limited trades on forward P/E -2.1, PEG 1.39, price-to-book 0.55; fundamentals show net margin 0.0%, return on equity -77.3%, revenue growth 633.5% year on year.

Analyst consensus: 3 analysts have a mean 12-month price target of A$0.11 (+392.7% vs the last close; range A$0.06 – A$0.20), consensus rating “none”.

Our screen: WATCH (score 0) — Late-stage immuno-oncology assets offer meaningful upside if trial execution and partnership momentum continue.

Computed from end-of-day data; not personal advice.

12-month price chart

0.40 0.02 FebMarAprMayJunJulAugSepOct
Daily close, 2026-02-08 → 2026-10-26 (AUD). Range 0.02 – 0.40.

Monthly returns

Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
-86.80%+20.00%-16.70%+0.00%+0.00%+0.00%-40.00%-33.30%

Fundamentals

Market cap
$33.9M
P/E (ttm)
-2.1
Forward P/E
-2.1
EPS (ttm)
$-0.05
Price / book
0.55
PEG
1.39
Beta
2.30
Net margin
0.0%
ROE
-77.3%
Revenue growth
633.5%
Revenue (ttm)
$19.9M
Free cash flow
$-36,994,360
Debt / equity
2%
52-wk range
$0.02 – $0.47
Volume
461,355
Avg volume (3m)
9,420,318

Analyst price target

Mean target
$0.11
Low
$0.06
High
$0.20
Analysts
3
Consensus
NONE

Technical signals

RSI (14)
35.7
vs 50-day MA
-42.50%
1-mo return
-32.35%
3-mo return
-50.00%
Volume z-score
-1.20

About Immutep Limited

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia.

Sector: Healthcare · Industry: Biotechnology · Australia · Website

Related Biotech picks

CSL.AXCSL LimitedMSB.AXMesoblast LimitedIMR.AXImricor Medical SystemSLD.AXSaluda Medical, Inc.NUZ.AXNeurizon Therapeutics NEU.AXNeuren PharmaceuticalsDXB.AXDimerix LimitedNYR.AXNyrada Inc.

Browse: all ASX stocks · Biotech picks · today's movers

General information only (Australia). This is general information, not financial product advice. It doesn't consider your objectives, financial situation or needs — consider its appropriateness and seek licensed advice before acting. Not a recommendation to buy or sell any financial product.

Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.